101 related articles for article (PubMed ID: 36945661)
21. Can reactogenicity predict immunogenicity after COVID-19 vaccination?
Hwang YH; Song KH; Choi Y; Go S; Choi SJ; Jung J; Kang CK; Choe PG; Kim NJ; Park WB; Oh MD
Korean J Intern Med; 2021 Nov; 36(6):1486-1491. PubMed ID: 34038996
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries.
Dag Berild J; Bergstad Larsen V; Myrup Thiesson E; Lehtonen T; Grøsland M; Helgeland J; Wolhlfahrt J; Vinsløv Hansen J; Palmu AA; Hviid A
JAMA Netw Open; 2022 Jun; 5(6):e2217375. PubMed ID: 35699955
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
[TBL] [Abstract][Full Text] [Related]
24. Homologous COVID-19 BNT162b2 mRNA Vaccination at a German Tertiary Care University Hospital: A Survey-Based Analysis of Reactogenicity, Safety, and Inability to Work among Healthcare Workers.
Niekrens V; Esse J; Held J; Knobloch CS; Steininger P; Kunz B; Seggewies C; Bogdan C
Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632406
[TBL] [Abstract][Full Text] [Related]
25. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
Baldolli A; Fournier A; Verdon R; Michon J
Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study.
Assawasaksakul T; Lertussavavivat T; Sathitratanacheewin S; Oudomying N; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Avihingsanon Y; Assawasaksakul N; Buranapraditkun S; Kittanamongkolchai W
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746461
[TBL] [Abstract][Full Text] [Related]
27. Recipient-Reported Reactogenicity of Different SARS-CoV-2 Vaccination Regimens among Healthcare Professionals and Police Staff in Germany.
Rau K; von Heeringen E; Bühler N; Wagenpfeil S; Becker SL; Schneitler S
Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514963
[TBL] [Abstract][Full Text] [Related]
28. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers.
Wi YM; Kim SH; Peck KR
Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452055
[TBL] [Abstract][Full Text] [Related]
29. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
Saita M; Yan Y; Ito K; Sasano H; Seyama K; Naito T
J Infect Chemother; 2022 Jan; 28(1):116-119. PubMed ID: 34580011
[TBL] [Abstract][Full Text] [Related]
30. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study.
Yechezkel M; Mofaz M; Painsky A; Patalon T; Gazit S; Shmueli E; Yamin D
Lancet Respir Med; 2023 Feb; 11(2):139-150. PubMed ID: 36410364
[TBL] [Abstract][Full Text] [Related]
31. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
32. Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.
Ascaso-Del-Rio A; García-Pérez J; Pérez-Olmeda M; Arana-Arri E; Vergara I; Pérez-Ingidua C; Bermejo M; Castillo de la Osa M; Imaz-Ayo N; Riaño Fernández I; Astasio González O; Díez-Fuertes F; Meijide S; Arrizabalaga J; Hernández Gutiérrez L; de la Torre-Tarazona HE; Mariano Lázaro A; Vargas-Castrillón E; Alcamí J; Portolés A;
EClinicalMedicine; 2022 Sep; 51():101542. PubMed ID: 35795398
[TBL] [Abstract][Full Text] [Related]
33. Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination.
Parés-Badell O; Zules-Oña R; Armadans L; Pinós L; Borrás-Bermejo B; Otero S; Rodrigo-Pendás JÁ; Vivet-Escalé M; Cossio-Gil Y; Agustí A; Aguilera C; Campins M; Martínez-Gómez X
Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 36016105
[TBL] [Abstract][Full Text] [Related]
34. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
[TBL] [Abstract][Full Text] [Related]
35. A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222.
Nantanee R; Jantarabenjakul W; Jaru-Ampornpan P; Sodsai P; Himananto O; Athipunjapong J; Sophonphan J; Nanthapisal S; Hirankarn N; Puthanakit T;
Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746522
[TBL] [Abstract][Full Text] [Related]
36. Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system.
Enayatrad M; Mahdavi S; Aliyari R; Sahab-Negah S; Nili S; Fereidouni M; Mangolian Shahrbabaki P; Ansari-Moghaddam A; Heidarzadeh A; Shahraki-Sanavi F; Fateh M; Khajeha H; Emamian Z; Behmanesh E; Sheibani H; Abbaszadeh M; Jafari R; Valikhani M; Binesh E; Vahedi H; Chaman R; Sharifi H; Emamian MH
BMC Infect Dis; 2023 Mar; 23(1):150. PubMed ID: 36899326
[TBL] [Abstract][Full Text] [Related]
37. BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
Vizcarra P; Haemmerle J; Velasco H; Velasco T; Fernández-Escribano M; Vallejo A; Casado JL
Vaccine; 2021 Dec; 39(51):7367-7374. PubMed ID: 34802792
[TBL] [Abstract][Full Text] [Related]
38. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.
Terpos E; Karalis V; Ntanasis-Stathopoulos I; Evangelakou Z; Gavriatopoulou M; Manola MS; Malandrakis P; Gianniou DD; Kastritis E; Trougakos IP; Dimopoulos MA
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203547
[TBL] [Abstract][Full Text] [Related]
40. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Oyebanji OA; Wilson B; Keresztesy D; Carias L; Wilk D; Payne M; Aung H; Denis KS; Lam EC; Rowley CF; Berry SD; Cameron CM; Cameron MJ; Schmader KE; Balazs AB; King CL; Canaday DH; Gravenstein S
Aging Clin Exp Res; 2021 Nov; 33(11):3151-3160. PubMed ID: 34652783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
